Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib plus all-trans retinoic acid in metastatic castration-resistant prostate cancer
ChiCTR2100046779Phase 4Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of fluzoparib and tretinoin in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Objective response rate. Started Apr 2021; status: recruiting.
02
Drugs
fluzoparibtretinoin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR2100046779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046779.